
    
      PRIMARY OBJECTIVE:

      I. Assess the response rate and the duration of response in patients with idiopathic
      myelofibrosis treated with sunitinib malate.

      SECONDARY OBJECTIVE:

      I. Assess the safety of sunitinib malate in these patients.

      OUTLINE: This is an open-label, multicenter study.

      Patients receive oral sunitinib malate once daily for 6 weeks. Treatment repeats every 6
      weeks in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed for 4 weeks.
    
  